Buy Jupiter Life Line Hospitals; target of Rs 340: Choice Institutional Equities

Key Investment Pillars

• Faster ramp-up at Dombivli: Dombivli’s operating trajectory is improving faster than initially anticipated, with quarterly EBITDA losses narrowing down, alongside occupancy reaching around 35%.
• Improving utilization across established hospitals: Mature hospitals, such as Thane and Pune, continue to operate at high occupancy levels, limiting volume-led growth, with pricing and inflation remaining the primary growth drivers.
• Gradual shift towards super specialties: The planned addition of advanced specialties, including oncology and organ transplantation at Dombivli, offers an opportunity to deepen clinical capabilities and improve revenue per occupied bed over time.
• Multi-hospital expansion: JLHL’s planned expansion across Pune South, Mira-Bhayandar, and BKC provides multiple avenues for capacity-led growth.

Thesis Validation Checklist

• ARPOB growth: Steady ARPOB growth driven by case mix improvement, with expected revenue expansion at a CAGR of 23.4% over FY26–FY29E.
• EBITDA margin: EBITDA growth supported by scale benefits, with expected EBITDA margin improvement over the medium term.
• Occupancy and utilization: Improving occupancy and utilization across established hospitals, alongside successful execution of expansion plans.
• Debt levels and funding: Management’s ability to manage debt levels and secure funding for expansion plans, with a focus on internal cash generation and available funding. Investors should watch for these signals over the next ~12 months to see if the thesis is playing out.